NASDAQ:HELP

Cybin Q2 2027 Earnings Results & Report

Cybin logo
$7.20 -0.47 (-6.13%)
Closing price 04:00 PM Eastern
Extended Trading
$7.21 +0.01 (+0.11%)
As of 04:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cybin missed analyst earnings expectations in its Q2 2027 results, released November 13, 2026. The company reported EPS of -$1.41 versus the -$0.67 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2027
Time
After Market Closes
Conference Call Date
Conference Call
6:00 AM ET

Cybin EPS Results

Actual EPS
-$1.41
Consensus EPS
-$0.67
Beat/Miss
Missed by -$0.74
One Year Ago EPS
N/A
EPS Beat Rate
1 of last 8 quarters

Cybin Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Cybin Q2 2027 Earnings FAQ

Cybin (NASDAQ:HELP) reported earnings of -$1.41 per share for Q2 2027, missing the consensus estimate of -$0.67. The report was announced on Friday, November 13, 2026.

Cybin Earnings Headlines

My public warning after 55 years of watching the markets
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.tc pixel
Cybin (NASDAQ:HELP) Cut to Strong Sell at Wall Street Zen
See More Cybin Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cybin? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cybin and other key companies, straight to your email.

About Cybin

Cybin (NASDAQ:HELP), which changed its name to Helus Pharma, is a clinical-stage biopharmaceutical company developing psychedelic-based treatments for mental health conditions. Its research focuses on designing and evaluating investigational compounds intended to address conditions including depression and anxiety disorders.

The company’s pipeline has included CYB003, a deuterated psilocin analog being studied for major depressive disorder, and CYB004, an investigational DMT-based treatment studied for generalized anxiety disorder. These compounds remain investigational and are not approved medicines.

Founded in 2019, the company has conducted clinical development activities in multiple countries. Doug Drysdale has served as its chief executive officer.

View Cybin Profile